Fig. 1 · Structure

Documents & Downloads

MF63

Cat. No. A11488 CAS 892549-43-8

MPGES-1 inhibitor

MF63 is a selective mPGES-1 inhibitor with an IC50 of 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme, respectively.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 50 μM Inhibition of PGF synthase in IL1-beta treated human A549 cell microsome assessed as inhibition of PGF2alpha production after 1 min in presence of 50% FBS [PMID: 21295979]
A549 IC50 0.42 μM Inhibition of mPGES1 in IL1-beta treated human A549 cell microsome assessed as inhibition of PGE2 production after 1 min in presence of 50% FBS [PMID: 21295979]
A549 IC50 56 nM Inhibition of mPGES-1 in human A549 cells assessed as decrease in IL1beta induced PGE2 release preincubated for 30 mins followed by IL-1beta addition after 16 to 20 hrs by HTRF method [PMID: 28400234]
A549 IC50 56 nM Inhibition of mPGES-1 in human A549 cells assessed as reduction in interleukin-1 beta-induced PGE2 production incubated for 30 mins followed by IL-1beta stimulation for 16 to 20 hrs in presence of 2% fetal bovine serum by HTRF assay [PMID: 27865703]
A549 IC50 76 nM Inhibition of mPGES1 in rhIL-1beta-stimulated human A549 cells assessed as PGE2 level treated for 18 hrs after 30 mins pre-incubation with rhIL-1beta by EIA method [PMID: 26653180]
CHO IC50 1.9 nM Inhibition of human recombinant mPGES-1 expressed in CHO cells assessed as reduction in conversion of PGH2 to PGE2 incubated for 10 mins followed by substrate addition measured after 1 min in presence of GSH [PMID: 27865703]
HEK293 IC50 4.3 nM Inhibition of microsomal PGES1 transfected in human HEK293 cells assessed as PGE2 production after 60 mins by HTRF assay [PMID: 22137787]
Sf9 IC50 1.59 μM Inhibition of purified mPGES-1 (1 to 152) (unknown origin) extracted from detergent-solubilized baculovirus-infected insect Sf9 cell membranes using PGH2 as substrate assessed as PGE2 production after 2.5 mins by LC/MS analysis [PMID: 25961169]

In Vitro Studies

In primary OA chondrocytes, IL‐1β + MF63 compared with IL‐1β alone yielded gene expression FC 3.68 for MT1B and FC 2.15 for IL36RN. In BMDMs, MTT assessment showed no difference in viability between the drug groups (MF63, MK886) and the control group. In BHK cells, MF63 triggered F508del-CFTR trafficking to the same level as glafenine. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

MF63 and MT1B Expression in OA Chondrocytes

Cell-based study · primary OA chondrocytes; n = 10 [1]

Primary OA chondrocytes were treated with IL‐1β + MF63 for 24 h and compared with IL‐1β alone. MT1B gene expression showed FC 3.68, with FDR‐adjusted P‐value <0.0001.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MT1B; Gene expression levelsReported result FC 3.68; FDR‐adjusted P‐value <0.0001[1]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Co-treatment
Other interventions in this design: IL‐1β. Compound effect isolated by the comparison: IL‐1β + MF63; IL‐1β.
Reported limits
Not stated in the sentences used: dose, route, vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: MF63

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

METHODS > Next‐generation sequencing and data analysis (S11, S13); TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r1)

MT1B; Gene expression levels: MT1B; Gene expression levels; comparator: IL‐1β — TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r1)

MF63 and BMDM Viability

Cell-based study · BMDM (10⁴ cells per well) [2]

BMDM viability following MF63 treatment was assessed using the MTT assay. No difference was observed between the drug groups (MF63, MK886) and the control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability of MF63 (1 × 10−9 M)-treated BMDMs was assessed using the MTT assayReported result no difference between the drug groups (MF63, MK886) and the control group[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 × 10−9 M
Method
Following treatment with MF63
Co-treatment
Other interventions in this design: macrophage colony-stimulating factor 20 ng/mL; lipopolysaccharide 1 μg/mL. Compound effect isolated by the comparison: between the drug groups (MF63, MK886) and the control group.
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: MF63

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Culture of bovine BMDMs (S10, S11); Materials and methods > Cell viability assay (S17, S18); Results > Selection of drug concentrations of mPGES-1 inhibitors in Escherichia coli infected BMDM (S41); Figure 1 legend (S80)

Cell viability of MF63 (1 × 10−9 M)-treated BMDMs was assessed using the MTT assay: Cell viability of MF63 (1 × 10−9 M)-treated BMDMs was assessed using the MTT assay; comparator: control group — Results > Selection of drug concentrations of mPGES-1 inhibitors in Escherichia coli infected BMDM (S41); Figure 1 legend (S80)

MF63 and F508del-CFTR Trafficking in BHK Cells

Cell-based study · BHK cells [3]

BHK cells were treated with MF63 at 10 μM for 24 h. MF63 triggered F508del-CFTR trafficking to the same level as glafenine.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
surface F508del-CFTRReported result inhibition of PGES 1, 2, and 3 by MF63 triggered F508del-CFTR trafficking to the same level as glafenine (n = 4)[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: MF63

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Glafenine corrects F508del-CFTR via the arachidonic acid pathway (S92); Materials and methods > High throughput screening assay (S155, S156); Figure 5 legend (S256)

surface F508del-CFTR: surface F508del-CFTR; comparator: untreated control cells — Results > Glafenine corrects F508del-CFTR via the arachidonic acid pathway (S92); Figure 5 legend (S256)

MF63 and IL36RN Expression in OA Chondrocytes

Cell-based study · primary OA chondrocytes; n = 10 [1]

Primary OA chondrocytes were treated with IL‐1β + MF63 for 24 h and compared with IL‐1β alone. IL36RN gene expression showed FC 2.15, with FDR‐adjusted P‐value <0.0001.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL36RN; Gene expression levelsReported result FC 2.15; FDR‐adjusted P‐value <0.0001[1]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Co-treatment
Other interventions in this design: IL‐1β. Compound effect isolated by the comparison: IL‐1β + MF63; IL‐1β.
Reported limits
Not stated in the sentences used: dose, route, vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: MF63

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

METHODS > Next‐generation sequencing and data analysis (S11, S13); TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r15)

IL36RN; Gene expression levels: IL36RN; Gene expression levels; comparator: IL‐1β — TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r15)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 892549-43-8
Applications MPGES-1 inhibitor
Formula C23H11ClN4
Molecular Weight 378.81
SMILES
C1=CC=C2C(=C1)C3=C(C=CC(=C3)Cl)C4=C2N=C(N4)C5=C(C=CC=C5C#N)C#N

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Tuure L, Pemmari A, Hämäläinen M, et al. Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. Br J Pharmacol (2020). PMID: 32449517 DOI: 10.1111/bph.15142 Source material
  2. [2] Yang X, Li X, Guo L, et al. Investigating the role of the mPGES-PGE₂-EP4 pathway in Escherichia coli-induced mastitis in dairy cows: insights for non-antibiotic therapeutic strategies. Front Vet Sci (2025). PMID: 40666730 DOI: 10.3389/fvets.2025.1628028 Source material
  3. [3] Carlile GW, Yang Q, Matthes E, et al. The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway. Sci Rep (2022). PMID: 35302062 DOI: 10.1038/s41598-022-08661-8 Source material

Added to your cart

View Cart Checkout
Loading...